An 8-week, randomized, double-blind, parallel-group, multicenter study assessing the efficacy and safety of aliskiren 75 mg, 150 mg, and 300 mg in patients 65 years of age with essential hypertension, using 24-hour ABPM, with lisinopril 10 mg as a reference